Douglas Tremblay

2.3k total citations
100 papers, 1.0k citations indexed

About

Douglas Tremblay is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Douglas Tremblay has authored 100 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Genetics, 57 papers in Hematology and 33 papers in Molecular Biology. Recurrent topics in Douglas Tremblay's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers), Acute Myeloid Leukemia Research (41 papers) and Kruppel-like factors research (19 papers). Douglas Tremblay is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers), Acute Myeloid Leukemia Research (41 papers) and Kruppel-like factors research (19 papers). Douglas Tremblay collaborates with scholars based in United States, India and Philippines. Douglas Tremblay's co-authors include John Mascarenhas, Leonard Naymagon, Thomas D. Schiano, Erin Moshier, Maaike van Gerwen, Mathilda Alsen, Eric M. Genden, C. C. Little, Joshua Barlow and Nicole Zubizarreta and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Hepatology.

In The Last Decade

Douglas Tremblay

93 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Tremblay United States 16 336 303 259 204 146 100 1.0k
Leonard Naymagon United States 17 398 1.2× 146 0.5× 345 1.3× 217 1.1× 184 1.3× 38 1.1k
Erika Borlenghi Italy 19 491 1.5× 216 0.7× 159 0.6× 119 0.6× 462 3.2× 59 1.2k
Rita Van Damme‐Lombaerts Belgium 23 339 1.0× 98 0.3× 197 0.8× 208 1.0× 231 1.6× 61 1.9k
Anthony D. Sung United States 19 429 1.3× 94 0.3× 88 0.3× 174 0.9× 274 1.9× 93 1.1k
Neşe Yaralı Türkiye 16 491 1.5× 301 1.0× 99 0.4× 93 0.5× 135 0.9× 137 1.1k
Mallika Sekhar United Kingdom 16 286 0.9× 327 1.1× 33 0.1× 178 0.9× 68 0.5× 39 705
Rut Norda Sweden 23 410 1.2× 207 0.7× 56 0.2× 52 0.3× 52 0.4× 44 1.4k
Man Fai Lam China 26 121 0.4× 36 0.1× 306 1.2× 168 0.8× 190 1.3× 54 1.8k
Cristina Royo Spain 19 52 0.2× 273 0.9× 108 0.4× 191 0.9× 271 1.9× 37 1.2k
Nicolas Maillard France 22 345 1.0× 77 0.3× 120 0.5× 151 0.7× 59 0.4× 84 1.9k

Countries citing papers authored by Douglas Tremblay

Since Specialization
Citations

This map shows the geographic impact of Douglas Tremblay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Tremblay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Tremblay more than expected).

Fields of papers citing papers by Douglas Tremblay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Tremblay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Tremblay. The network helps show where Douglas Tremblay may publish in the future.

Co-authorship network of co-authors of Douglas Tremblay

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Tremblay. A scholar is included among the top collaborators of Douglas Tremblay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Tremblay. Douglas Tremblay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tremblay, Douglas, Robert P. Hasserjian, & Raajit K. Rampal. (2025). Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management. Leukemia. 39(6). 1311–1324. 1 indexed citations
2.
Handa, Shivani, Michelle Becker, Jonathan Feld, et al.. (2024). Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights. JCO Precision Oncology. 8(8). e2300234–e2300234. 3 indexed citations
3.
Handa, Shivani, Christoph Schaniel, Joseph Tripodi, et al.. (2024). HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis. Leukemia. 39(3). 663–674. 1 indexed citations
4.
5.
Martin, Lily, et al.. (2023). An overlooked mimic? Autoimmune myelofibrosis—A scoping review of the literature. European Journal Of Haematology. 111(5). 706–714. 2 indexed citations
6.
Sastow, Dahniel & Douglas Tremblay. (2023). Emerging Treatment Options for Myelofibrosis: Focus on Anemia. Therapeutics and Clinical Risk Management. Volume 19. 535–547. 2 indexed citations
7.
Tremblay, Douglas, et al.. (2023). The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment. Blood Reviews. 62. 101117–101117. 7 indexed citations
8.
Zubizarreta, Nicole, Erin Moshier, Douglas Tremblay, et al.. (2022). Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients. Clinical Lymphoma Myeloma & Leukemia. 22(12). 903–911. 8 indexed citations
9.
Liu, Bian, Bethany Percha, Stephanie Pan, et al.. (2021). Cardiovascular Disease and Severe Hypoxemia Are Associated With Higher Rates of Noninvasive Respiratory Support Failure in Coronavirus Disease 2019 Pneumonia. Critical Care Explorations. 3(3). e0355–e0355. 7 indexed citations
10.
Tremblay, Douglas, et al.. (2021). Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia. The Oncologist. 26(5). 406–421. 4 indexed citations
11.
Tremblay, Douglas, Lukas Ronner, Nikolai A. Podoltsev, et al.. (2021). Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research. 109. 106629–106629. 2 indexed citations
12.
Abu‐Zeinah, Ghaith, Richard T. Silver, Douglas Tremblay, et al.. (2021). A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients. Blood. 138(Supplement 1). 3619–3619. 3 indexed citations
13.
Doroshow, Deborah B., Andrew Schmidt, Ziad Bakouny, et al.. (2020). LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS). Annals of Oncology. 31. S1204–S1204. 4 indexed citations
14.
Leng, Siyang, Erin Moshier, Douglas Tremblay, et al.. (2020). Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. Clinical Lymphoma Myeloma & Leukemia. 20(10). e734–e751. 2 indexed citations
15.
Moshier, Erin, Samantha E. Jacobs, Douglas Tremblay, et al.. (2020). Practicing Antimicrobial Stewardship: De-Escalating Antibiotics in Patients With Acute Myeloid Leukemia and Neutropenic Fever. Open Forum Infectious Diseases. 7(5). ofaa138–ofaa138. 7 indexed citations
16.
Tremblay, Douglas, Leonard Naymagon, Kevin Troy, et al.. (2020). The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis. Blood Coagulation & Fibrinolysis. 31(3). 213–218. 15 indexed citations
17.
Gerwen, Maaike van, Mathilda Alsen, C. C. Little, et al.. (2020). Outcomes of Patients With Hypothyroidism and COVID-19: A Retrospective Cohort Study. Frontiers in Endocrinology. 11. 565–565. 69 indexed citations
18.
Tremblay, Douglas. (2017). Novel Targets in Multiple Myeloma. 12(10). 1 indexed citations
19.
Tremblay, Douglas, Bridget K. Marcellino, & John Mascarenhas. (2017). Pharmacotherapy of Myelofibrosis. Drugs. 77(14). 1549–1563. 3 indexed citations
20.
Fellers, John P., et al.. (2002). The Potato virus Y  M S N R NIb‐replicase is the elicitor of a veinal necrosis‐hypersensitive response in root knot nematode resistant tobacco. Molecular Plant Pathology. 3(3). 145–152. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonard Naymagon Breakdown of academic impact, for papers by Erika Borlenghi Breakdown of academic impact, for papers by Rita Van Damme‐Lombaerts Breakdown of academic impact, for papers by Anthony D. Sung Breakdown of academic impact, for papers by Neşe Yaralı Breakdown of academic impact, for papers by Mallika Sekhar Breakdown of academic impact, for papers by Rut Norda Breakdown of academic impact, for papers by Man Fai Lam Breakdown of academic impact, for papers by Cristina Royo Breakdown of academic impact, for papers by Nicolas Maillard
Rankless by CCL
2026